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Patterns of complementary and alternative medicine use among patients undergoing cancer treatment
This study aimed to assess the prevalence of complementary and alternative medicine (CAM) use in a
representative cancer population prior to and within 6 months of diagnosis. A total of 304 newly diagnosed
cancer patients from two UK cancer centres completed a postal survey. Of them, 100 patients (32.9%) used CAM
before their cancer diagnosis, 59 of these CAM users continued post diagnosis. Twenty-nine individuals who had
not used CAM before began to use it after their cancer diagnosis, creating a total of 88 (28.9%) CAM users in this
sample. Reasons for not using CAM included lack of interest, lack of information or endorsement from
professionals and satisfaction with conventional care. For those using CAM before diagnosis but not afterwards,
the most common reason was a lack of expert guidance on what was safe to use. The use of CAM medicines
bought from health food and other retail outlets was high. Complementary and alternative medicine use in
cancer patients is common and demonstrates a complex pattern, but CAM use is not significantly greater than
in the general population. Some patients purchase CAM medicines without seeking medical advice, thus risking
drug interactions. Research to generate information on safety and efficacy of CAM is required.
Keywords: complementary medicine, alternative medicine, cancer, cancer treatment.
INTRODUCTION
Complementary and alternative medicines (CAM) are
widely used among the general population, indeed their
use is increasing. Surveys conducted in the UK, the US
and in Australia indicate that between 10% and 25% of
the population use CAM each year, and 50% of the popu-
lation use CAM at some point in their lifetime (Eisenberg
et al. 1993; Fisher & Ward 1994; MacLennan et al. 1996).
A recent population-based survey in England (Thomas
et al. 2001) found that 14% of adults had visited one of
eight specified complementary therapists, and 28% of
adults surveyed had used a therapy or over the counter
remedy in the previous 12 months. Only 10% of contacts
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with CAM therapists were through the UK National
Health Service (NHS), the remainder being paid for
through out-of-pocket expenditure (Thomas et al. 2001).
The prevalence of CAM use has led to questions as to the
efficacy and safety of this largely unregulated form of
health care, as well as whether such therapies should be
integral to formal systems of health care such as the NHS.
Studies of patients with cancer have suggested a higher
use of CAM than the normal population (Cassileth et al.
1984; Downer et al. 1994; Rees et al. 2000; Sollner et al.
2000; Paltiel et al. 2001; Malassiotis 2005). A systematic
review of 26 studies from 13 countries revealed that
between 7% and 63% of patients with cancer use CAM
with a median of 31% for the patients sampled (Ernst &
Cassileth 1998). However, these studies involve selective
patient samples and differing definitions of CAM, distort-
ing true estimates of prevalence of CAM use among
people with cancer. This study set out to explore the ways
in which CAM is used by a nationally representative
group of newly diagnosed cancer patients undergoing
active conventional treatment.
METHODS
This was a questionnaire-based cross-sectional epidemio-
logical study. Patients were sampled on a quota basis, to
ensure that the distribution of cancer sites mirrored
figures from National Cancer Statistics 2001 (Cancer UK
2001). Data were collected from a sample of recently diag-
nosed (within 6 months) patients attending two cancer
treatment centres in the South of England. Local research
ethics approval was given at both study centres
(Southampton and South-west Hampshire (052/03/w) and
West Hertfordshire Hospitals NHS Trust (EC2003-34)).
Initially, study centre 1 was refused permission for the
researchers to approach patients directly and discuss the
study, so questionnaires were distributed in sealed enve-
lopes by reception staff as patients arrived for treatment.
After 3 months of low recruitment, a case was made to the
local research ethics committee (LREC) that relying on
reception staff to distribute the sealed envelopes led to the
situation where the research team were unable to know
whether or not patients had been approached and, there-
fore, it was unclear whether the low recruitment was due
to patients declining to take part or that they had been
overlooked by busy clinic staff. As a result, the restriction
was removed by the LREC. Both committees specified
that no contact was allowed with patients after distribu-
tion of the questionnaire and no reminders could be sent.
The stringency applied by both LRECs meant that recruit-
ment was lower than would have been the case if the
research team had been allowed to approach patients after
questionnaire distribution and to follow-up non-response.
All patients provided written informed consent.
Those recruited completed a postal questionnaire
including closed and open-ended questions about their use
of CAM both before and since receiving a cancer diagno-
sis. The questionnaire was developed and piloted follow-
ing a review of published questionnaires including
estimating CAM use, and was based on both the House
of Lords Science and Technology Select Committee
(2000) definition of CAM and Thomas et al.’s (2001)
questionnaire-based survey.
Patient characteristics and frequencies of CAM use
before and after diagnosis were tabulated. The Townsend
Material Deprivation Index (Townsend et al. 1988) (based
on patients’ postcode) was used as a measure of socio-
economic status, and categorized by quintiles within the
study population. As distribution of time from diagnosis
to screening was skewed, data were presented using
medians and interquartile ranges (IQR). In order to deter-
mine which patient characteristics predicted CAM use
before and after diagnosis, factors were first investigated
in univariate analyses and tested using the c2 test (or c2
test for trend where appropriate), the t-test for age and the
non-parametric Mann–Whitney test for time from diagno-
sis. Forward stepwise logistic regression analysis was then
carried out, including all of the patient characteristics to
determine which factors remained significant indepen-
dent predictors for CAM use before and after diagnosis.
Analysis of open-ended questions relating to the reasons
why patients used or did not use CAM used a content-
analysis approach. Statements recorded on questionnaires
were collated and grouped into like categories, where they
were summarized and then described thematically.
Counts of the number of patients with similar responses
were made to identify the most commonly occurring
themes.
RESULTS
A total of 304 patients returned their questionnaire by
post. Over the study period, and across both centres, this
represents 51% of all patients approached for the study.
However, the initial response rate at study centre 1 was
very low due to LREC restrictions, but once these were
removed, the response rate approached that of study
centre 2 at 65%. As with other such surveys, patients were
less likely to return questionnaires if they were male, had
advanced disease and did not have breast cancer. Demo-
graphic data about the patient sample are contained in
Table 1 and were similar in both centres, but with a lower
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education level of patients from study centre 2 (P = 0.007).
The mean age of the patients was 60 years, 55.6% were
female, 72.7% were married (or living with a partner). The
quota sample was achieved for most of the less common
cancer sites (e.g. bladder, non-Hodgkins lymphoma, head
and neck), but some of the most frequent sites were over-
represented (breast, prostate), while others were under-
represented (lung), particularly in centre 1.
PATTERNS OF CAM USE
Four patterns of CAM use were identified: patients who
used CAM before diagnosis and continued to do during
cancer treatment, patients who used CAM before diagno-
sis but stopped using CAM during treatment; patients
who used CAM for the first time following diagnosis; and
finally patients who did not use CAM at any time.
CAM use before diagnosis
One hundred patients (32.9%) reported that they had used
CAM before their diagnosis (9.9% often and 23.0% some-
times) (Table 2). This reflects the proportion of the general
population using CAM found in other studies; 33 (10.3%)
reported purchasing over-the-counter (OTC) medicines
(Eisenberg et al. 1993; Fisher & Ward 1994; MacLennan
et al. 1996; Sollner et al. 2000; Thomas et al. 2001).
A wide variety of CAM therapies were reported, the
most common being aromatherapy (28.0%), reflexology
(26.0%), chiropractic medicine (24.0%), acupuncture
(23.0%), herbal medicine (22.0%) and yoga (20.0%). The
median number of therapies was two (IQR 1–4, range
1–10). Of the 100 patients who had used CAM before
diagnosis, 45.0% had disclosed their CAM use to their
general practitioner (GP), and 59 of these patients contin-
ued to use CAM after their diagnosis.
Factors predicting CAM use before diagnosis
Patients who used CAM before their diagnosis of cancer
were more likely to be younger (P = 0.05), female (P =
0.006) and with a higher educational level (P < 0.001)
(Table 3). There was a non-significant difference between
numbers using CAM before diagnosis in study centre 1
(36.5%) compared with study centre 2 (29.5%) (P = 0.27).
Regression analysis including all the factors in Table 3
showed that gender (P = 0.007) and education (P < 0.001)
were the only significant independent predictors of CAM
use before diagnosis. Marital, socio-economic and employ-
ment status did not predict pre-diagnostic use.
CAM use following diagnosis
Eighty-eight (28.9%) reported CAM use after their diagno-
sis; 29 of these individuals had not used CAM before. A
Table 1. Demographic and clinical characteristics
Demographic/clinical characteristic Total (%) n = 304
Age (years)
<50 64 (21.1)
50–59 71 (23.4)
60–69 82 (27.0)
70 85 (28.0)
Unknown 2 (0.7)
Mean (SD) 60.0 (13.5)
Gender
Female 169 (55.6)
Male 134 (44.1)
Unknown 1 (0.3)
Marital status
Married/re-married/living with partner 221 (72.7)
Single/widowed/separated/divorced 80 (26.3)
Unknown 3 (1.0)
Highest educational qualification
Less than compulsory school education 42 (13.8)
Compulsory school education 97 (31.9)
Post compulsory school education 83 (27.3)
University/postgraduate level 70 (23.1)
Unknown 12 (3.9)
Paid work
Retired 151 (49.7)
Not working at present 34 (11.2)
Yes 116 (38.2)
Unknown 3 (1.0)
Recruitment clinic
Chemotherapy 142 (46.7)
Radiotherapy 149 (49.0)
Other 9 (3.0)
Unknown 4 (1.3)
Cancer site Required* Actual
Breast 46 (15%) 76 (25.0)
Prostate 27 (9%) 42 (13.8)
Large bowel 40 (13%) 42 (13.8)
Lung 43 (14%) 22 (7.2)
Head and neck 9 (3%) 11 (3.6)
Bladder 15 (5%) 10 (3.3)
Oesophagus 9 (3%) 8 (2.6)
Non-Hodgkin’s Lymphoma 9 (3%) 7 (2.3)
Pancreas 9 (3%) 4 (1.3)
Stomach 12 (4%) 3 (1.0)
Unknown 4 (1.3)
Other 85 (28%) 75 (24.7)
Stage
I 16 (5.3)
II 64 (21.0)
III 48 (15.8)
IV 34 (11.2)
Unknown 142 (46.7)
Metastases
Yes 34 (11.2)
No 153 (50.3)
Unknown 117 (38.5)
Time from diagnosis to screening (months) 3.0 (2.2–4.2)
Median (IQR) [range] [0.1–9.9]
*Based on national incidence.
IQR, interquartile range.
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wide variety of CAM therapies were used, the most
common being reflexology (35.2%), aromatherapy (30.7%)
and herbal medicine (25.0%) (Table 4). Again, patients
tended to use more than one CAM with a median number
of two (IQR 1–3, range 1–9).
Of the 88 patients who had used CAM since their diag-
nosis, 42.0% had sought help from a CAM practitioner,
and 45.5% had bought OTC medicines. These prevalence
figures for OTC remedy use are similar to those observed
previously by Werneke et al. (2004). There were no signifi-
cant differences in patient characteristics between those
who did and did not consult practitioners or buy OTC
medicines. Of the 40 patients who had bought OTC treat-
ments, in 75% of cases these were purchased from outlets
where pharmacological advice was unlikely to be avail-
able, i.e. health food stores (57.5%) and supermarkets
(17.5%), rather than pharmacists (25%). Over-the-counter
products purchased included nutritional medicines
(48.8% of the 40 patients) and herbal medicines (25.6% of
the 40 patients). It is noteworthy that 56/88 (63.6%) of the
patients used therapies provided by the study centres
(aromatherapy, reflexology and counselling). Almost all
patients using CAM therapies said that they found them
helpful, with only a few patients unsure of their value.
Patients found out about CAM from members of their
family (25.0%) and friends (28.4%). Twenty-seven per cent
of patients had read about particular therapies and then
decided to use them. They also received information
about CAM from healthcare professionals, such as doctors
(10%), nurses (35.2%) and ‘others’ (12.5%). Of the 88
patients who had used CAM since diagnosis, 16 (18.2%)
had informed their GP of their CAM use, 29 (33.0%)
had informed their consultant and 42 (47.7%) had also
informed a nurse. Twenty-three of the 88 patients (26.1%)
who had used CAM since their diagnosis had not informed
a health professional.
Factors predicting CAM use following diagnosis
Patients who used CAM following their cancer diagnosis
were more likely to be younger, female, with a higher
educational level, currently not working, to have breast
cancer and to have used CAM before diagnosis (all
P < 0.001). They were also more likely to have early stage
disease (P = 0.009) and to perceive their illness to be affect-
ing their day-to-day lives (P = 0.01). There were signifi-
cantly more CAM users at study centre 1 compared with
centre 2 (P = 0.01) (Table 5). There were no significant
differences in CAM use according to marital status or
socio-economic status. Complementary and alternative
medicine use before diagnosis (P < 0.001), age (P = 0.006),
gender (P < 0.001) and study centre (P = 0.02) were inde-
pendent predictors of CAM use after diagnosis after regres-
sion analysis using all factors on Table 5. When CAM use
before diagnosis was omitted from the stepwise regression
model, significant factors included gender (P < 0.001), edu-
cation (P = 0.003), employment (P = 0.01) and disease stage
(P = 0.03).
Comparison between CAM use before and
after diagnosis
Fifty-nine of the 100 patients reporting CAM use before
diagnosis used it after diagnosis and 41 did not. Indepen-
dent predictors of continued CAM use were younger age
(P = 0.01), female gender (P = 0.001) and early-stage disease
(P = 0.01). Twenty-nine patients who were not using CAM
before diagnosis had taken up using CAM. Following
regression analysis, the only significant predictor for
Table 2. Complementary and alternative medicine (CAM) use
before diagnosis of cancer
Total (%)
Used CAM before diagnosis n = 304
Often 30 (9.9)
Sometimes 70 (23.0)
Never 200 (65.8)
Unknown 4 (1.3)
Which CAMs used* n = 100
Aromatherapy 28 (28.0)
Reflexology 26 (26.0)
Chiropractic 24 (24.0)
Acupuncture 23 (23.0)
Herbal medicine 22 (22.0)
Yoga 20 (20.0)
Homeopathy 18 (18.0)
Bach/other flower remedies 18 (18.0)
Osteopathy 17 (17.0)
Body work therapies 16 (16.0)
Other 14 (14.0)
Nutritional medicine 9 (9.0)
Counselling 7 (7.0)
Hypnotherapy 4 (4.0)
Meditation 4 (4.0)
Healing 4 (4.0)
Chinese herbal medicine 4 (4.0)
Shiatsu 3 (3.0)
Maharishi Ayurvedic medicine 2 (2.0)
Ayurvedic medicine 2 (2.0)
Dowsing 2 (2.0)
Kinesiology 2 (2.0)
Anthroposophical medicine 1 (1.0)
Naturopathy 1 (1.0)
Traditional Chinese medicine 1 (1.0)
Crystal therapy 1 (1.0)
Spiritual 1 (1.0)
*Percentages add to more than 100% as more than one CAM
could be used.
CORNER et al.
© 2009 The Authors
Journal compilation © 2009 Blackwell Publishing Ltd
274
previous non-users taking up CAM was early-stage disease
(P = 0.02).
Reflexology (which was available at both centres), was
the most common therapy used before and after diagnosis
by older patients, men, those with disease sites other than
breast and prostate, and those with less than compulsory
education. Herbal medicine and reflexology were the most
common therapies used before and after diagnosis by
those in the most deprived socio-economic category.
Motivations for using CAM
In response to open-ended questions about the motiva-
tions for using CAM can broadly be categorized as follows:
some patients adopted CAM as a strategy to enhance or
have an additive effect on conventional treatment, thus
improving the chance of cure from cancer. Others used
CAM to help cope with the stress of having cancer, to help
with feeling more relaxed and in control of the situation;
it was also felt that being stressed may make successful
treatment less likely or might mean that cancer was more
likely to return. Some had used CAM to assist in reducing
the side effects of cancer treatment, especially if conven-
tional measures for managing these had failed.
How an individual came to use CAM varied. Whether
this was offered in the treatment centre and endorsed by
the treatment team appeared to be important in encour-
aging individuals to use CAM and encouraged individu-
Table 3. Complementary and alternative medicine (CAM) use before diagnosis according to patient characteristics
Patient characteristic
No. using CAM before
diagnosis/total¶ (%) P-value*
Age (years) 0.05†
<50 24/64 (37.5)
50 35/70 (50.0)
60 20/82 (24.4)
70 21/83 (25.3)
Unknown 0/1 (0)
Mean (SD) in user vs. nonusers 57.8 (12.1) vs. 61.0 (14.0)
Gender 0.006
Female 67/166 (40.4)
Male 33/134 (24.6)
Marital status 0.91
Married/re-married/living with partner 73/221 (33.0)
Single/widowed/separated/divorced 27/78 (34.6)
Unknown 0/1 (0)
Highest educational qualification <0.001‡
Less than compulsory school education 5/42 (11.9)
Compulsory school education 28/97 (28.9)
Post compulsory school education 32/83 (38.6)
University/postgraduate level 32/69 (46.4)
Unknown 3/9 (33.3)
Paid work 0.08
Retired 42/150 (28.0)
Not working at present 16/34 (47.1)
Yes 41/115 (35.7)
Unknown 1/1 (100)
Townsend deprivation index (quintile) 0.07
1 = least deprived 20/50 (40.0)
2 19/53 (35.8)
3 21/56 (37.5)
4 12/50 (24.0)
5 = most deprived 14/52 (26.9)
Unknown 14/39 (35.9)
Study centre 0.27
1 54/147 (36.7)
2 46/153 (30.1)
Unknown categories not included in the significance tests.
*P-value corresponds to c2 test unless otherwise specified.
†t-test.
‡c2 test for trend.
¶CAM use before diagnosis unknown for 4 patients.
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als who would not have otherwise considered it to used
CAM. In these instances, the fact that CAM was not
charged for was significant. Family members, friends and
fellow patients also importantly influenced and encour-
aged the use of CAM. Other individuals with a strong
commitment to managing their health themselves
sought out particular therapies, and some were prepared
to pay for these on an ongoing basis. A small group of
individuals had used CAM on a long-standing basis to
help with particular health problems, such as back prob-
lems, headaches or stress, and they continued to use
CAM after their diagnosis.
An important observation from this study is that often
there was no direct connection between the particular
CAM therapy chosen and the purpose for which it was
being used. In other words, patients were not using CAM
as a form of specific therapy, mostly, CAM was used for
general, non-specific, whole body or system purposes,
such as ‘boosting the immune system’ or ‘helping reduce
stress’.
Reasons for not using CAM
In response to open-ended questions about the reasons for
not using CAM, low interest in CAM was cited by 54
patients (25%) as their main reason for non-use. Patients
indicated that they were satisfied with their conventional
treatment and confident of the doctor’s management of
their illness, and therefore did not see the value of any
additional treatment. Other reasons included a lack of
information about safety and the cost and availability of
CAM. The most common reason given for use before
diagnosis but not after was a lack of expert guidance on
what was safe to use.
DISCUSSION
This study presents a different picture for CAM use fol-
lowing a diagnosis of cancer than previous published
reports (Ernst & Cassileth 1998; Malassiotis 2005). Nearly
half of those who had used CAM in the past did not use
CAM after a diagnosis of cancer. However, others who had
never previously used CAM started using it. While groups
previously associated with CAM use (women, younger
people and those with early-stage disease) predominate,
this does not mean that other groups are uninterested in
using CAM. There was also evidence of use of these thera-
pies prior to diagnosis among those least expected to use
CAM, such as older people, men and people living in
deprived areas. The most important predictive factor for
CAM use is use prior to diagnosis, suggesting that CAM
may be part of people’s usual self-care rather than a spe-
cific strategy to manage cancer.
Reflexology and aromatherapy massage were the most
commonly used CAM therapies, and were available as
part of the package of care offered in the two cancer treat-
ment settings. Their availability would very probably
have reassured patients that these two therapeutic inter-
ventions were safe to use during cancer treatment.
However, much of the identified CAM use was OTC rem-
edies purchased from health food stores and supermarkets
where there will be very limited medical help or guidance
on how these products may be best utilized. Supplements,
such as garlic and cod liver, have an anticoagulant effect
and may interfere with conventional anticoagulant thera-
pies (Fugh-Berman 2000), while Hypericum (St John’s
Wort), often taken to help with depression, is known to
act on the cytochrome P450 system, and may affect the
metabolism of some hormones, antibiotics and cytotoxic
agents (Izzo & Ernst 2001). Echinacea interferes with cor-
ticosteroid and monoclonal antibody treatments used to
treat lymphomas (Jellin et al. 2003). As only 18% told
their GPs and 48% of patients told their consultants about
their CAM use, we consider that this relatively high level
of OTC supplement use may expose cancer patients to a
risk of drug interaction.
Table 4. Complementary and alternative medicine (CAM) use
after diagnosis of cancer
Total (%)
Used CAM after diagnosis n = 304
Yes 88 (28.9)
No 215 (70.7)
Unknown 1 (0.3)
CAMs used after diagnosis* n = 88
Reflexology 31 (35.2)
Aromatherapy 27 (30.7)
Herbal medicine 22 (25.0)
Other 14 (15.9)
Body work therapies 12 (13.6)
Nutritional medicine 12 (13.6)
Homeopathy 10 (11.4)
Meditation 9 (10.2)
Yoga 9 (10.2)
Bach/other flower remedies 9 (10.2)
Counselling 8 (9.1)
Acupuncture 6 (6.8)
Healing 3 (3.4)
Spiritual 3 (3.4)
Osteopathy 2 (2.3)
Chinese herbal medicine 2 (2.3)
Chiropractic 1 (1.1)
Hypnotherapy 1 (1.1)
Shiatsu 1 (1.1)
Maharishi Ayurvedic medicine 1 (1.1)
Anthroposophical medicine 1 (1.1)
*Percentages add to more than 100% as more than one CAM
could be used.
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Table 5. Complementary and alternative medicine (CAM) use after diagnosis according to patient characteristics
Patient characteristic
No. using CAM after
diagnosis/total¶ (%) P-value*
CAM user before diagnosis <0.001
No 29/200 (14.5)
Yes 59/100 (59.0)
Unknown 0/3 (0)
Age (years) <0.001†
<50 27/64 (42.2)
50 30/71 (42.3)
60 20/82 (24.4)
70 11/85 (12.9)
Unknown 0/1 (0)
Mean (SD) in user vs. nonusers 55.3 (12.3) vs. 61.9 (13.5)
Gender <0.001
Female 72/169 (42.6)
Male 16/134 (11.9)
Marital status 0.24
Married/re-married/living with partner 60/221 (27.1)
Single/widowed/separated/divorced 28/80 (35.0)
Unknown 0/2 (0)
Highest educational qualification 0.002‡
Less than compulsory school education 4/42 (9.5)
Compulsory school education 25/97 (25.8)
Post compulsory school education 30/83 (36.1)
University/postgraduate level 27/70 (38.6)
Unknown 2/11 (18.2)
Paid work <0.001
Retired 31/151 (20.5)
Not working at present 20/34 (58.8)
Yes 36/116 (31.0)
Unknown 1/2 (50.0)
Recruitment clinic 0.14
Chemotherapy 36/142 (25.4)
Radiotherapy 50/148 (33.8)
Other 1/9 (11.1)
Unknown 1/4 (25.0)
Townsend deprivation index (quintile) 0.39
1 = least deprived 16/50 (32.0)
2 17/53 (32.1)
3 16/56 (28.6)
4 9/50 (18.0)
5 = most deprived 16/53 (30.2)
Unknown 14/41 (34.1)
Cancer site <0.001
Breast 40/76 (52.6)
Prostate 6/42 (14.3)
Large bowel 10/42 (23.8)
Other 32/140 (22.9)
Unknown 0/3 (0)
Stage 0.009
I/II 34/80 (42.5)
III/IV 19/82 (23.2)
Unknown 35/141 (24.8)
Metastases 0.33
Yes 8/34 (23.5)
No 49/153 (32.0)
Unknown 31/116 (26.7)
Time from diagnosis to screening (months) 0.39§
Median (IQR) in users vs. nonusers 3 (2.2–4.9) vs. 3 (2.2–4.1)
Has illness affected day to day life? 0.01
Yes 53/172 (30.8)
Occasionally 24/67 (35.8)
No 7/54 (13.0)
Unknown 4/10 (40.0)
Study centre 0.01
1 53/147 (36.1)
2 35/156 (22.4)
Unknown categories not included in the significance tests.
*P-value corresponds to c2 test unless otherwise specified.
†t-test.
‡c2 test for trend.
§Mann–Whitney test.
¶CAM use after diagnosis unknown for 1 patient.
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The study has limitations. Just over half of patients
approached participated in the study. A substantial and
significant difference in the interpretation of the new
ethics procedures meant that study centre 1 was unable to
recruit to full capacity in the initial stages. We suspect
that lower response rates may become the norm for future
surveys at some centres until there is some national agree-
ment on the interpretation of ethics procedures for
surveys. However, in spite of these problems, and our new
and unique observations, this study has considerable con-
sistency with previously published data; for instance,
CAM use in early breast and prostate cancer is approxi-
mately double that for other cancer sites and the preva-
lence of OTC herbal and supplement use is consistent
with previous reports (Werneke et al. 2004). We therefore
consider that our low response rate may not be a signifi-
cant limitation when considering the generalizability of
these data to all patients with cancer. Comparison of non-
responders with those responding to the questionnaire
suggests that patients with advanced disease and who
were male were less likely to participate as with most
questionnaire-based supportive care studies in cancer, and
therefore results relating to these groups should be inter-
preted with caution.
CONCLUSIONS
This is the first study to report the use of CAM among a
representative sample of cancer patients attending UK
cancer treatment settings. Complementary and alternative
medicine use among cancer patients is not substantially
greater than has been suggested for the UK population as a
whole (Thomas et al. 2001). Previous surveys (Ernst &
Cassileth 1998; Malassiotis 2005) may have overestimated
CAM use as a consequence of their non-representative
sampling techniques. However, we can confirm that CAM
use among patients undergoing cancer treatment is
common, with approximately one-third using CAM, par-
ticularly those with early breast cancer. Surprisingly, CAM
use in this population is not predicted by socio-economic
status. The primary reason for this relatively low CAM use
may be concern among patients about what CAM therapies
are safe or advisable to use alongside conventional treat-
ment and a clear reluctance to discuss this with their
conventional healthcare professionals. Of those who used
CAM, less than half of them shared this fact with their
oncology treatment team; these disclosure rates are similar
to those reported previously (Eng et al. 2001). Those
patients who purchased OTC remedies tended to do so
from places where no healthcare professional was available
to provide medical advice.
This study suggests that there is a need for further
research with respect to CAM use among cancer patients
in order to generate information for patients about what
they may safely use alongside conventional treatment.
Over half our respondents decided to use CAM without
discussing it with their cancer treatment team, and
healthcare professionals involved in managing patients
with cancer would do well to consider discussing CAM
use with their patients in a supportive and positive
manner.
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